Schoenberg Mark 4
4 · UroGen Pharma Ltd. · Filed Nov 20, 2025
Insider Transaction Report
Form 4
Schoenberg Mark
Chief Medical Officer
Transactions
- Sale
Ordinary Shares
2025-11-19$25.00/sh−10,000$250,000→ 139,025 total
Footnotes (2)
- [F1]Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 and $25.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.